Expression of taxol resistance gene 1 correlates with gastric cancer patient clinical outcome and induces taxol resistance

Molecular Medicine Reports

Volumn 3, Issue 6, 2010, Pages 1071-1078

  Bai, Zhi Gang ^a   Qu, Xiang ^a   Han, Wei ^a   Ma, Xue Mei ^a   Zhao, Xiao Mu ^a   Zhang, Zhong Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Multidrug resistance; Taxol resistance; Taxol resistance gene 1; Thrombospondin 1

Indexed keywords

CAPECITABINE; COMPLEMENTARY DNA; DOCETAXEL; GREEN FLUORESCENT PROTEIN; IRINOTECAN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; OXALIPLATIN; PACLITAXEL; SMALL INTERFERING RNA; TAXANE DERIVATIVE; THROMBOSPONDIN 1;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE ARREST; DRUG CYTOTOXICITY; FEMALE; GASTRECTOMY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH BIOPSY; STOMACH CANCER; TAXOL RESISTANCE GENE 1; TREATMENT OUTCOME;

EID: 78649467300     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.371     Document Type: Article

References (20)

1. Gonzalez R and Mansfield P: Adjuvant and neoadjuvant therapy for gastric cancer. Surg Clin North Am 85: 1033-1051, 2005.
2. Glimelius B, Ekstr MK, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
3. Murad A, Santiago F, Petroianu A, Rocha P, Rodrigues M and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 2006.
4. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
5. Garcia AA, Leichman CG, Lenz HJ, et al: Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 31: 275-278, 2001.
6. Yamada Y, Shirao K, Ohtsu A, et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12: 1133-1137, 2001.
7. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
8. Lih C-J, Wei W and Cohen SN: Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 20: 2082-2095, 2006.
9. Papadaki C, Mavroudis D, Trypaki M, et al: Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res 15: 3827-3833, 2009.
10. Bai Z and Ye Y: Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis. APMIS 115: 1383-1390, 2007.
11. Greenberger L, Lothstein L, Williams S and Horwitz S: Distinct p-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 85: 3762-3766, 1988.
12. El-Rehim D, Ball G, Pinder S, et al: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340-350, 2005.
13. Choi J, Lim H, Joo H, et al: Expression of multidrug resistance- associated protein1, p-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 86: 1578-1585, 2002.
14. Fan K, Fan D, Cheng L and Li C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res 20: 4809-4814, 2000.
15. Hutchinson E: A taxing problem. Nat Rev Cancer 6: 578-579, 2006.
16. Monzó M, Rosell R, Sánchez JJ, et al: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793, 1999.
17. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
18. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP: Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monographs: 55-61, 1993.
19. Kutuk O and Letai A: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994, 2008.
20. Hudis C and Dang C: The taxane limbo: how low can we go? J Natl Cancer Inst 100: 761-763, 2008.